CHAUDHURI BHASKAR 4

What Happened
Bhaskar Chaudhuri, a director of Tarsus Pharmaceuticals, had 2,954 restricted stock units (RSUs convertibles to common shares) vest on June 12, 2026 and those RSUs were converted into 2,954 shares. The filing also shows a simultaneous disposition of 2,954 shares at $0.00 (no cash proceeds reported). This was an RSU settlement/derivative conversion rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-12 (reported on Form 4 filed 2026-06-16).
• Reported transactions: conversion/exercise of derivative (code M) — 2,954 shares acquired; 2,954 shares disposed at $0.00.
• Price/Value: acquisition shows N/A; disposition shows $0.00 (no cash proceeds reported in the filing).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnotes: shares were issued pursuant to settlement of vested RSUs granted June 12, 2025 that vested in full on the one‑year anniversary, subject to continuous service.
• Timeliness: filing appears timely (transaction 6/12/2026; filed 6/16/2026).

Context
RSUs are compensation that convert to shares when they vest. It’s common for insiders to have shares withheld or surrendered to cover taxes at vesting; the filing shows a disposition at $0, which likely reflects internal withholding rather than an open‑market sale. Such RSU settlements are routine compensation events and do not necessarily signal a change in insider sentiment.